Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting

Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting

In intermediate risk hormone receptor (HR) positive, HER2 negative breast cancer (BC), the decision regarding adjuvant chemotherapy might be facilitated by multigene expression tests. In all, 142 intermediate risk BCs were investigated using the PAM50-based multigene expression test Prosigna® in a p...

Full description

Bibliographic Details
Main Authors: Ramona Erber, Miriam Angeloni, Robert Stöhr, Michael P. Lux, Daniel Ulbrich-Gebauer, Enrico Pelz, Agnes Bankfalvi, Kurt W. Schmid, Robert F. H. Walter, Martina Vetter, Christoph Thomssen, Doris Mayr, Frederick Klauschen, Peter Sinn, Karl Sotlar, Katharina Stering, Albrecht Stenzinger, Marius Wunderle, Peter A. Fasching, Matthias W. Beckmann, Oliver Hoffmann, Rainer Kimmig, Nadia Harbeck, Rachel Wuerstlein, Fulvia Ferrazzi, Arndt Hartmann
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:International Journal of Molecular Sciences
Subjects:
Prosigna
PAM50
multigene expression analysis
immunohistochemistry
IHC
tumor grade
Online Access:https://www.mdpi.com/1422-0067/23/15/8716

Internet

https://www.mdpi.com/1422-0067/23/15/8716

Similar Items